Le Lézard
Classified in: Health
Subjects: CCA, FVT

Nevro to Report Operating Results for the Second Quarter 2018


REDWOOD CITY, Calif., July 19, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical technology company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the second quarter of 2018 after market close on Thursday, August 2, 2018. Company management will host a conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Thursday, August 2, 2018.

Investors interested in listening to the conference call may do so by dialing (866) 393-4306 for U.S. callers or (734) 385-2616 for international callers (Conference ID: 9865398), or logging into the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical technology company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® system and Senza IItm system are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

Investor Relations Contact:
Nevro Investor Relations
(650) 433-3247
[email protected]

.

 

SOURCE Nevro Corp.


These press releases may also interest you

at 03:00
Todd Britten, DMD, a board-certified periodontist and dental implant specialist in...

at 03:00
SK chemicals (CEO Ahn Jae-hyun), Dongsung Chemical (Co-CEOs Baek Jin-woo and Lee Man-woo), and BYN Black Yak (Chairman Kang Tae-sun, hereinafter Black Yak) announced on the 18th that they've developed sustainable footwear materials using the...

at 02:55
First quarter  Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas.Sales per business area, in local currencies was...

at 02:05
PureTech Health plc ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024. A presentation and conference call to discuss the results...

at 02:05
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024. Highlights for the first quarter of 2024      Strong commercial...

at 01:30
The shares in Aker ASA will be traded ex-dividend NOK 15.50 as from today, 18 April 2024. Investor contact:Fredrik Berge, Head of Investor Relations Aker ASA Tel: +47 450 32 090 E-mail: [email protected] Media contact:Atle Kigen, Head of...



News published on and distributed by: